ASCO Genitourinary Symposium

PSMA-Targeted Treatment Improves Bone-Related Pain in Metastatic, Castration-Resistant Prostate Cancer

March 7th 2022

Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.

Drug Duo Sparks Encouraging Outcomes in Treatment of Clear Cell Kidney Cancer

March 1st 2022

In a recent clinical trial, treatment with Bavencio plus Inlyta produced promising outcomes in the presurgical treatment of patients with non-metastatic, clear cell renal cell carcinoma.

Cabometyx Before Surgery May Shrink Tumors With No Disease Progression in Advanced Kidney Cancer

February 22nd 2022

Treatment with Cabometyx before surgery in patients with advanced renal cell carcinoma, a type of kidney cancer, may provide benefits, although further research is required before a decision is made about its role in presurgical treatment.

Updated Results on Lenvima-Keytruda Combo ‘Still Encouraging’ for Patients With Advanced Kidney Cancer, Expert Says

February 22nd 2022

Although the data failed to identify a predictive biomarker in patients with advanced kidney cancer, an expert from Memorial Sloan Kettering Cancer Center in New York notes that the results indicate that no one should be excluded from receiving Lenvima plus Keytruda.

Immunotherapy Agent Misses Study Survival Goal in Advanced Penile Cancer

February 22nd 2022

Tecentriq failed to meet the progression-free survival goal in a trial analyzing the immunotherapy agent in advanced squamous cell carcinoma of the penis.

Even in the Prescence of Health Complications and Other Medications, Nubeqa Maintains Safety, Efficacy in Prostate Cancer Treatment

February 21st 2022

Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.

Fotivda Boosts Survival and Has ‘Interesting’ – and Tolerable – Safety Profile for Kidney Cancer Treatment

February 21st 2022

Fotivda – a TKI drug that was approved last year – not only improved survival outcomes, but was also very tolerable in terms of side effects for patients with metastatic renal cell carcinoma.

Immunotherapy Combinations Offer ‘Hope and Promise’ for Patients with Advanced Renal Cell Carcinoma

February 23rd 2021

Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.

Cabometyx Significantly Prolongs Survival Over Sutent in Rare Form of Kidney Cancer

February 18th 2021

The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.

Padcev Continues to Show Promise in Patients with Previously Treated Bladder Cancer

February 15th 2021

Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.

Lenvima Plus Keytruda Associated With Better Results Than Sutent Alone in Patients With Advanced Type of Kidney Cancer

February 13th 2021

The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.

Novel Therapy Demonstrates Limited Activity and Poor Safety Outcomes in Patients With Metastatic Renal Cell Carcinoma

February 13th 2021

Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.

Communication And Support Can Help Patients With Cancer Improve Their Quality of Life During Treatment

February 13th 2021

For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.

New Options for Renal Cell Carcinoma Could Offer Hope, But Sequencing and a Personalized Approach Are Critical

February 12th 2021

Clinical trials remain the gold standard when it comes to finding new treatment options for patients, particularly when it comes to renal cell carcinoma. But even if the results are positive and this combination proves to be beneficial, patients should still discuss all of their options with their oncologist to find the right sequence of treatment, says one expert.

Zytiga and Prednisone Plus Erleada Reduces Risk of Disease Progression in Prostate Cancer Subtype

February 12th 2021

The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

Opdivo-Cabometyx Combo Improves Quality of Life in Kidney Cancer Subtype

February 12th 2021

Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.

Front-Line Immunotherapy Improves Survival in Kidney Cancer Subtype, Versus Certain Targeted Therapies

February 11th 2021

Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.

Starting Treatment With Lenvima at a Higher Dose Improves Quality of Life and Symptom Control in Type of Kidney Cancer

February 11th 2021

A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.

New Combination Could Prove Beneficial After Immunotherapy in Patients with Clear Cell RCC

February 11th 2021

The combination of Lenvima plus everolimus was found to be an acceptable treatment option for patients who have previously received immunotherapy for clear cell renal cell carcinoma, according to the findings of an exploratory analysis of a phase 2 trial presented virtually at the 2021 ASCO Genitourinary Cancers Symposium.